文献速递类风湿关节炎

PREVENT计算器在类风湿关节炎中的心血管风险预测表现

Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2026-02-17

基于美国退伍军人健康管理局、Medicare和全国死亡索引数据(2006-2020),将30,687例类风湿关节炎(RA)患者与231,752例对照按年龄、性别和入组年份匹配,评估PREVENT计算器的校准与判别能力。结果显示PREVENT在RA中低估总体心血管病(CVD)、动脉粥样硬化性心血管病(ASCVD)和心力衰竭(HF)风险,且对ASCVD和HF的敏感性较差;纳入糖化血红蛋白后预测表现改善。

要点

  • PREVENT在RA中低估总体CVD(SIR 1.83,95%CI 1.79-1.88)、ASCVD(SIR 2.25,95%CI 2.19-2.32)和HF(SIR 1.41,95%CI 1.36-1.46)风险。
  • PREVENT对ASCVD敏感性61.9%、对HF敏感性63.2%,对ASCVD预测表现不如PCE(SIR 1.38,95%CI 1.34-1.41;敏感性76.0%)。
  • 纳入糖化血红蛋白后PREVENT表现改善:总体CVD SIR 1.21(95%CI 1.18-1.24)、ASCVD SIR 1.45(95%CI 1.41-1.50)、HF SIR 0.79(95%CI 0.76-0.82),ASCVD敏感性80.3%。

核心结论

  • PREVENT计算器在RA患者中低估CVD风险,与现有风险计算器表现欠佳一致,应考虑优先使用包含糖化血红蛋白的PREVENT。

研究设计与样本

  • 利用美国退伍军人健康管理局、Medicare和全国死亡索引数据(2006-2020),将RA患者与最多10例对照按年龄、性别和入组年份匹配,比较PREVENT的校准(SIR和观察/预测事件数)与判别(敏感性和Harrel C统计量),并与PCE比较。

主要发现

  • 共纳入30,687例RA患者和231,752例非RA对照,在超过200万人年中识别28,061例ASCVD和13,851例HF结局。
  • PREVENT在RA中低估总体CVD(SIR 1.83,95%CI 1.79-1.88)、ASCVD(SIR 2.25,95%CI 2.19-2.32)和HF(SIR 1.41,95%CI 1.36-1.46)风险,且较对照更明显。
  • PREVENT对ASCVD敏感性61.9%、对HF敏感性63.2%,对ASCVD预测表现不如PCE(SIR 1.38,95%CI 1.34-1.41;敏感性76.0%)。
  • PREVENT的NRI为5.3%;657例发生ASCVD的重分类患者中626例被不当重分类为低危或临界风险。
  • 纳入糖化血红蛋白后PREVENT表现改善:总体CVD SIR 1.21(95%CI 1.18-1.24)、ASCVD SIR 1.45(95%CI 1.41-1.50)、HF SIR 0.79(95%CI 0.76-0.82),ASCVD敏感性80.3%。

临床怎么用

  • 在RA患者心血管风险评估中,应考虑优先使用包含糖化血红蛋白的PREVENT计算器。
  • 需注意PREVENT在RA中可能低估CVD风险,尤其对ASCVD和HF的敏感性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate performance of the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator in rheumatoid arthritis (RA). METHODS: Patients with RA were matched up to 10 controls on age, sex, and enrollment year using National Veterans Health Administration, Medicare, and National Death Index data (2006-2020). Ten-year estimated cardiovascular disease (CVD) risk was calculated using PREVENT. Calibration (standardized incidence ratio [SIR] and observed/predicted events) and discrimination (sensitivity and Harrel's C-statistics) were compared between RA cases and controls. PREVENT performance was compared with the Pooled Cohort Equations (PCE) for atherosclerotic CVD (ASCVD) prediction in RA, including net reclassification index (NRI) calculation. RESULTS: Among 30,687 patients with RA and 231,752 patients without RA, 28,061 ASCVD and 13,851 heart failure (HF) outcomes were identified over >2 million person-years. PREVENT underestimated overall CVD (SIR 1.83, 95% confidence interval [CI] 1.79-1.88), ASCVD (SIR 2.25, 95% CI 2.19-2.32) and HF risk (SIR 1.41, 95% CI 1.36-1.46) to a greater degree in RA compared with controls and exhibited poor sensitivity for ASCVD (61.9%) and HF (63.2%) development. PREVENT performance was poorer for ASCVD prediction compared with the PCE (SIR 1.38, 95% CI 1.34-1.41, sensitivity 76.0%). NRI for PREVENT was modest (5.3%). Among 657 reclassified patients who experienced ASCVD, 626 were inappropriately reclassified as low or borderline risk. PREVENT performance significantly improved when including hemoglobin A1c (overall CVD: SIR 1.21, 95% CI 1.18-1.24; ASCVD: SIR 1.45, 95% CI 1.41-1.50; HF: SIR 0.79, 95% CI 0.76-0.82; sensitivity ASCVD 80.3%). CONCLUSION: PREVENT underestimates CVD risk in RA, consistent with suboptimal performance of existing risk calculators. Preferential use of PREVENT including hemoglobin A1c should be considered. Improving CVD risk stratification in RA remains a high priority.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Johnson TM, Frideres H, Roul P, et al. Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis. Arthritis Rheumatol. 2026. PMID: 41657109. doi:10.1002/art.70081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。